Raffles Medical Group Ltd BSL
SGX · Singapur · Gesundheitsdienstleistungen
SGD 0,8200-0,01 (-1,20 %)
Markt geschlossen· · SGD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · SGD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a supply agreement with Raffles Medical for its neurodegenerative brain imaging analysis software, Neurophet AQUA.
Potential Raffles Medical Group Ltd ( SGX:BSL ) shareholders may wish to note that the Executive Chairman & CEO, Choon...
Raffles Medical Group Ltd ( SGX:BSL ) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date...
In April 2026, global markets have experienced notable fluctuations, with major U.S. stock indexes reaching record highs due to positive economic data and strong performances in AI-linked stocks despite geopolitical tensions. The Russell 2000 Index, a key measure for small-cap stocks, has shown resilience with a year-to-date increase of over 12%, highlighting investor interest in smaller companies amid rising retail sales and robust corporate earnings. In this dynamic environment,...
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.